Table 1.
Demographics and baseline characteristics
| Healthy Japanese subjects | Subjects with stable schizophrenia | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Placebo | TAK-063 | All subjects | Placebo | TAK-063 | All subjects | |||||||||
| 3 mg | 10 mg | 20 mg | Total TAK-063 | 3 mg | 10 mg | 20 mg | 30 mg | 100 mg | Total TAK-063 | |||||
| Number | n = 6 | n = 8 | n = 8 | n = 8 | n = 24 | N = 30 | n = 9 | n = 7 | n = 8 | n = 7 | n = 8 | n = 8 | n = 38 | N = 47 |
| Age, mean (SD), years | 38.5 (11.5) | 36.3 (9.8) | 25.9 (9.5) | 34.6 (10.6) | 32.3 (10.6) | 33.5 (10.9) | 43.1 (11.3) | 43.4 (4.2) | 39.6 (9.9) | 44.6 (9.0) | 45.3 (8.2) | 39.4 (8.1) | 42.4 (8.1) | 42.5 (8.7) |
| Sex, % | ||||||||||||||
| Male | 83.3 | 75.0 | 100.0 | 100.0 | 91.7 | 90.0 | 55.6 | 57.1 | 50.0 | 85.7 | 62.5 | 87.5 | 68.4 | 66.0 |
| Female | 16.7 | 25.0 | 0 | 0 | 8.3 | 10.0 | 44.4 | 42.9 | 50.0 | 14.3 | 37.5 | 12.5 | 31.6 | 34.0 |
| Racea, % | ||||||||||||||
| Asian | 100 | 100 | 100 | 100 | 100 | 100 | 0 | 0 | 0 | 14.3 | 0 | 0 | 2.6 | 2.1 |
| Blackb | 0 | 0 | 0 | 0 | 0 | 0 | 88.9 | 85.7 | 62.5 | 57.1 | 87.5 | 87.5 | 76.3 | 78.7 |
| White | 0 | 0 | 0 | 0 | 0 | 0 | 11.1 | 14.3 | 37.5 | 28.6 | 12.5 | 0 | 18.4 | 17.0 |
| BMI, mean (SD), kg/m2 | 22.2 (2.8) | 24.8 (2.0) | 22.7 (2.6) | 24.1 (2.0) | 23.9 (2.3) | 23.5 (2.4) | 28.8 (5.7) | 31.1 (3.3) | 27.0 (3.5) | 27.9 (5.5) | 32.2 (4.2) | 27.8 (4.5) | 29.2 (4.5) | 29.1 (4.7) |
BMI body mass index, SD standard deviation
aSubjects could also report as “multiracial”
bOr African American